<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04387539</url>
  </required_header>
  <id_info>
    <org_study_id>SOF/SMV/DCV/RBV</org_study_id>
    <nct_id>NCT04387539</nct_id>
  </id_info>
  <brief_title>ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants</brief_title>
  <official_title>A Sofosbuvir-based Quadruple Regimen is Highly Effective in HCV Type 4-infected Egyptian Patients With DAA Treatment Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beni-Suef University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beni-Suef University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Experienced participants who had HCV GT4 infection were treated with
      Sofosbuvir/Simeprevir/Daclatasvir/Ribavirin (SOF/SMV/DCV/RBV)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Experienced participants, who had chronic infection with HCV GT4 , and failed prior DAA
      treatments, SOF/DCV (71/92) or SOF/SMV (15/92) or SOF/pegylated interferon/RBV (2/92) or
      SOF/RBV (4/92) were enrolled in the current study.

      In the present study, the regimen used was designed by the combination of triple DAAs with
      different mechanisms of action and non-overlapping resistance profiles, SOF/SMV/DCV, plus
      RBV.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">October 31, 2017</completion_date>
  <primary_completion_date type="Actual">October 31, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Each Treatment Arm</measure>
    <time_frame>12 weeks after last dose</time_frame>
    <description>SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) level &lt; 15 IU/m 12 weeks after the last dose of drugs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events in Each Treatment Arm</measure>
    <time_frame>Screening up to 12 weeks after last dose</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant clinical investigation after administering a pharmaceutical drugs Serious adverse event (SAE) is an event that results in death, life-threatening, requires hospitalization, or significant disability/incapacity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Viral relapse</measure>
    <time_frame>Up to 12 weeks after last dose</time_frame>
    <description>Viral relapse was HCV RNA level undetectable at End of Treatment (EOT) (≤ 15 IU/ml), but detectable HCV RNA ( &gt; 15 IU/ml) levels 12 weeks after planned EOT.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Chronic Hepatitis C Virus Infection</condition>
  <arm_group>
    <arm_group_label>Non-Cirrhotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SOF plus DCV/SMV/RBV regimen was administered to Egyptian non-cirrhotic experienced HCV GT4 participants for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cirrhotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SOF plus DCV/SMV/RBV regimen was administered to Egyptian cirrhotic experienced HCV GT4 participants for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOF/SMV/DCV/RBV</intervention_name>
    <description>SOF was given orally at a dose of 400 mg/day DCV was given orally at a dose of 60 mg/day SMV was given orally at a dose of 150 mg/day. RBV was given in a total daily oral dose of 600 mg/day up to 1,200 mg/day according to the participant's weight and tolerability.</description>
    <arm_group_label>Cirrhotic</arm_group_label>
    <arm_group_label>Non-Cirrhotic</arm_group_label>
    <other_name>Olysio is a trade name of simeprevir</other_name>
    <other_name>Sovaldi is a trade name of sofosbuvir</other_name>
    <other_name>Daklinza is a trade name of daclatasvir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Experienced Egyptian participants with HCV GT4 infection who had failed prior DAA
             treatments [SOF/DCV or SOF/SMV or SOF/pegylated interferon/RBV or SOF/RBV]

          -  Fibrosis-4 score in non-cirrhotic participants is &lt;1.45-3.25: (None or moderate
             fibrosis)

          -  Fibrosis-4 score in cirrhotic participants is &gt;3.25: (Advanced fibrosis or cirrhosis)

        Exclusion Criteria:

          -  HCV coinfected with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

          -  had any liver disease other than chronic HCV GT4 infection.

          -  had a history of liver decompensation

          -  serum a-fetoprotein (AFP) &gt; 100 ng/ml

          -  evidence of hepatocellular carcinoma

          -  major severe illness such as respiratory, renal, heart failure or autoimmune disease

          -  non-compliance with treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammed Abdel-Gabbar, Ass. Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biochemistry Dep., Faculty of Science, Beni-Suef University, P.O. Box 52621</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Health Administration at Beni-Seuf</name>
      <address>
        <city>Bani Sweif</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>http://www.journal-of-hepatology.eu/article/S0168-8278(18)30174-0/fulltext</url>
    <description>This link shows the investigation performed in the retreatment with SOF plus DCV/SMV/RBV regimen in EgyptianHCV GT4 participants</description>
  </link>
  <results_reference>
    <citation>Abdel-Moneim A, Aboud A, Abdel-Gabbar M, Zanaty MI, Ramadan M. A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure. J Hepatol. 2018 Jun;68(6):1313-1315. doi: 10.1016/j.jhep.2018.03.010. Epub 2018 Apr 3.</citation>
    <PMID>29625827</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 10, 2020</study_first_submitted>
  <study_first_submitted_qc>May 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <last_update_submitted>May 10, 2020</last_update_submitted>
  <last_update_submitted_qc>May 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beni-Suef University</investigator_affiliation>
    <investigator_full_name>Mohammed Abdel-Gabbar, Ph.D</investigator_full_name>
    <investigator_title>Associate Prof</investigator_title>
  </responsible_party>
  <keyword>Chronic HCV GT4</keyword>
  <keyword>Sofosbuvir</keyword>
  <keyword>Simeprevir</keyword>
  <keyword>Daclatasvir</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Simeprevir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

